/SRPT
SRPT Stock - Sarepta Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$21.04+3.44%
+$0.70 (+3.44%) • Dec 19
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.22
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).54
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.99
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+2.2%upside
Target: $21.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SRPT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$20.83 – $21.25
TARGET (TP)$21.50
STOP LOSS$19.36
RISK/REWARD1:0.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.53
52W High$129.84
52W Low$10.42
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.90B | $1.24B | $933.01M | $701.89M | $540.10M |
| Gross Profit | $1.58B | $1.09B | $793.02M | $604.84M | $476.72M |
| Gross Margin | 83.2% | 87.9% | 85.0% | 86.2% | 88.3% |
| Operating Income | $218.08M | $-267,824,000 | $-536,201,000 | $-459,710,000 | $-564,163,000 |
| Net Income | $235.24M | $-535,977,000 | $-703,488,000 | $-418,780,000 | $-554,128,000 |
| Net Margin | 12.4% | -43.1% | -75.4% | -59.7% | -102.6% |
| EPS | $2.47 | $-5.80 | $-8.03 | $-5.15 | $-7.11 |
Company Overview
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
14
39%
Hold / Neutral
16
44%
Sell / Underperform
6
17%
Analyst Consensus🔴 Bearish
14 Bullish22 Neutral/Bearish
Price Targets
$79
Average Target
↑ 275.4% Upside
Now
$5
Low
$79
Average
$224
High
Based on 40 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Wedbush | Initiation | Outperform | $32 |
| November 5th 2025 | Mizuho | Upgrade | Outperform | $26 |
| September 22nd 2025 | BMO Capital Markets | Upgrade | Outperform | $50 |
| July 29th 2025 | Barclays | Upgrade | Equal Weight | $22 |
| July 29th 2025 | Bernstein | Initiation | Market Perform | $13 |
| July 29th 2025 | H.C. Wainwright | Reiterated | Sell | $5 |
| July 29th 2025 | Oppenheimer | Upgrade | Outperform | $37 |
| July 29th 2025 | JP Morgan | Upgrade | Neutral | $24 |
| July 28th 2025 | Barclays | Downgrade | Underweight | $10 |
| July 25th 2025 | JP Morgan | Downgrade | Underweight | - |
| July 24th 2025 | Citigroup | Initiation | Sell | $7 |
| July 23rd 2025 | BofA Securities | Downgrade | Underperform | $10 |
| July 22nd 2025 | Barclays | Downgrade | Equal Weight | $18 |
| July 21st 2025 | UBS | Downgrade | Neutral | $12 |
| July 21st 2025 | Deutsche Bank | Downgrade | Hold | $9 |
Earnings History & Surprises
SRPTBeat Rate
78%
Last 18 quarters
Avg Surprise
+203.0%
EPS vs Estimate
Beats / Misses
14/4
Last 12 quarters
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q1 24
+3084.3%
$0.47vs$0.01
Q2 24
+625.6%
$0.73vs$0.10
Q3 24
+1201.1%
$0.07vs$0.01
Q4 24
+1139.7%
$0.62vs$-0.06
Q1 25
+8.7%
$1.50vs$1.38
Q2 25
-1077.1%
$-3.42vs$0.35
Q3 25
+82.0%
$2.02vs$1.11
Q4 25
-1400.0%
$-0.13vs$0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-1.03 | — | — | — |
Q4 2025 | Nov 3, 2025 | $0.01 | $-0.13 | -1400.0% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $1.11 | $2.02 | +82.0% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $0.35 | $-3.42 | -1077.1% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $1.38 | $1.50 | +8.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.06 | $0.62 | +1139.7% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $0.01 | $0.07 | +1201.1% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $0.10 | $0.73 | +625.6% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $0.01 | $0.47 | +3084.3% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $-1.66 | $-0.46 | +72.3% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-1.89 | $-0.27 | +85.7% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $-1.46 | $-0.97 | +33.6% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-1.28 | $-1.24 | +3.1% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-1.21 | $-2.94 | -143.0% | ✗ MISS |
Q3 2022 | Aug 2, 2022 | $-1.07 | $-2.65 | -147.7% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-1.35 | $-1.20 | +11.1% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-1.51 | $-1.42 | +6.0% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-1.86 | $-0.60 | +67.7% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-1.03 | $-1.02 | +1.0% | ✓ BEAT |
Latest News
'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
📈 PositiveBenzinga•Dec 16, 2025, 04:34 PM•Also: , ,
Sarepta Therapeutics shares are trading lower. The company announced a refinancing of approximately $291 million of 1.25% Convertible Senior Notes due 2027.
📉 NegativeBenzinga•Dec 11, 2025, 02:20 PM
Sarepta Therapeutics To Refinance $291.4M 1.25% Convertible Senior Notes Due 2027 Into 4.875% Convertible Senior Notes Due 2030
➖ NeutralBenzinga•Dec 11, 2025, 12:10 PM
Wedbush Initiates Coverage On Sarepta Therapeutics with Outperform Rating, Announces Price Target of $32
📈 PositiveBenzinga•Dec 9, 2025, 01:15 PM
FDA Approves Sarepta's ENDEAVOR Cohort 8 To Test Enhanced Immunosuppression In Non-Ambulatory Duchenne Patients
📈 PositiveBenzinga•Nov 25, 2025, 01:59 PM
Sarepta Therapeutics Shared Progress In Phase 1/2 Multiple Ascending Dose Study Of SRP-1003 (Formerly ARO-DM1), An Investigational Small Interfering RNA Therapeutic For Type 1 Myotonic Dystrophy
📈 PositiveBenzinga•Nov 24, 2025, 12:33 PM
Arrowhead Pharmaceuticals Earns $200M Milestone Payment From Sarepta Therapeutics
📈 PositiveBenzinga•Nov 24, 2025, 12:31 PM•Also:
FDA Approves New Safety Warning And Revised Indication That Limits Use For Elevidys Following Reports Of Fatal Liver Injury
📉 NegativeBenzinga•Nov 14, 2025, 06:47 PM
Barclays Maintains Equal-Weight on Sarepta Therapeutics, Lowers Price Target to $20
📉 NegativeBenzinga•Nov 5, 2025, 05:51 PM•Also:
Wells Fargo Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $45
➖ NeutralBenzinga•Nov 5, 2025, 03:27 PM
Guggenheim Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $19
➖ NeutralBenzinga•Nov 5, 2025, 03:17 PM
Mizuho Upgrades Sarepta Therapeutics to Outperform, Raises Price Target to $26
📈 PositiveBenzinga•Nov 5, 2025, 11:03 AM
Baird Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $15
📉 NegativeBenzinga•Nov 4, 2025, 05:22 PM
Market-Moving News for November 4th
➖ NeutralBenzinga•Nov 4, 2025, 12:24 PM•Also: ,
Sarepta Therapeutics shares are trading lower after the company reported Q3 financial results. Also, the company announced that its ESSENCE study did not achieve statistical significance on its primary endpoint.
📉 NegativeBenzinga•Nov 4, 2025, 11:10 AM
Sarepta plunges after late-stage Duchenne trial failure
📉 NegativeSeeking Alpha•Nov 3, 2025, 10:03 PM
Sarepta Therapeutics shares are trading lower after the company reported that its ESSENCE study did not achieve statistical significance on the primary endpoint.
📉 NegativeBenzinga•Nov 3, 2025, 09:40 PM
Sarepta Therapeutics shares are trading lower after the company reported Q3 financial results. Also, the company announced that its ESSENCE study did not achieve statistical significance on its primary endpoint.
📉 NegativeBenzinga•Nov 3, 2025, 09:38 PM
Sarepta Therapeutics Says ESSENCE Study Did Not Achieve Statistical Significance On Its Primary Endpoint; Says 'the study was impacted by the COVID-19 pandemic and, when COVID-impacted data is excluded, meaningful treatment effect is seen on the primary endpoint'
📉 NegativeBenzinga•Nov 3, 2025, 09:26 PM
Sarepta Therapeutics Q3 Adj. EPS $(0.13) Beats $(0.81) Estimate, Sales $399.356M Beat $338.710M Estimate
📈 PositiveBenzinga•Nov 3, 2025, 09:09 PM
Frequently Asked Questions about SRPT
What is SRPT's current stock price?
Sarepta Therapeutics, Inc. (SRPT) is currently trading at $21.04 per share. The stock has moved +3.44% today.
What is the analyst price target for SRPT?
The average analyst price target for SRPT is $21.50, based on 1 analyst.
What sector is Sarepta Therapeutics, Inc. in?
Sarepta Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SRPT's market cap?
Sarepta Therapeutics, Inc. has a market capitalization of $2.06 billion, making it a mid-cap company.
Does SRPT pay dividends?
No, Sarepta Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADPT
Adaptive Biotechnologies Corporation
$17.00
Mkt Cap: $2.6B
AGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
COGT
Cogent Biosciences, Inc.
$39.55
Mkt Cap: $5.6B
DNLI
Denali Therapeutics Inc.
$16.85
Mkt Cap: $2.5B
ETNB
89bio, Inc.
$14.84
Mkt Cap: $2.2B
IBRX
ImmunityBio, Inc.
$2.08
Mkt Cap: $2.0B
MLYS
Mineralys Therapeutics, Inc.
$36.83
Mkt Cap: $2.4B
RCUS
Arcus Biosciences, Inc.
$21.98
Mkt Cap: $2.4B
RXRX
Recursion Pharmaceuticals, Inc.
$4.26
Mkt Cap: $1.7B
Explore stocks similar to SRPT for comparison